Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network

Codis, a global contract development and manufacturing organization (CDMO), has successfully completed its acquisition of Catalent's Nottingham facility in the United Kingdom, with the deal value remaining undisclosed. The transaction, finalized on August 3, 2026, marks a significant expansion of Codis' integrated spray drying capabilities in Europe, enhancing its offerings in oral solid dose (OSD) development and small-scale commercial manufacturing.

The acquisition of the Nottingham site adds critical resources to Codis' operational portfolio, which already includes a commercial-scale spray drying facility in Haverhill, UK. The Nottingham team, with over two decades of expertise in formulation and clinical supply, is expected to bolster Codis' capabilities in delivering high-quality spray-dried and OSD solutions. This strategic move positions Codis to provide a comprehensive end-to-end pathway for customers, facilitating a seamless transition from development to commercial manufacturing.

Codis' investment in the Nottingham facility complements its ongoing expansion efforts in Haverhill, where a new GEA Pharma-SD® PSD-4 commercial spray dryer is scheduled for validation in 2027. The combination of these facilities establishes a robust framework for bioavailability enhancement solutions, enabling Codis to address the needs of clients working with poorly soluble molecules. This integrated approach is designed to streamline processes, reduce risks, and enhance the speed with which customers can bring their products to market.

The broader implications of this acquisition reflect a growing trend within the pharmaceutical and biotechnology sectors, where companies are increasingly seeking integrated solutions that combine development, manufacturing, and regulatory expertise. As the demand for innovative drug formulations rises, the ability to offer a comprehensive suite of services under one roof is becoming a competitive advantage. Codis' enhanced capabilities position it well to capitalize on this trend, potentially attracting a wider range of clients looking for efficient pathways to commercialization.

Overall, the acquisition of Catalent's Nottingham facility by Codis signifies a strategic enhancement of its service offerings in the European market. As the pharmaceutical landscape continues to evolve, Codis is poised to play a pivotal role in shaping the future of spray drying and OSD manufacturing, further solidifying its position as a leader in the CDMO sector.